Highlighted Text:
Show |
Hide
Full text loading...
Chapter 35 : Cryptococcosis in Experimental Animals: Lessons Learned
Authors:
Karl V. Clemons1,
David A. Stevens3
VIEW AFFILIATIONS
HIDE AFFILIATIONS
Affiliations:
1: California Institute for Medical Research, Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128;
2: Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305;
3: California Institute for Medical Research, Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128;
4: Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305
Content Type: Monograph
Publication Year:
2011
Category: Clinical Microbiology; Fungi and Fungal Pathogenesis
Book DOI:
10.1128/9781555816858
Chapter DOI:
10.1128/9781555816858.ch35
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Cryptococcosis in Experimental Animals: Lessons Learned, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap35-1.gif /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap35-2.gif
Abstract:
This chapter presents salient examples in the use and performance of animal models of cryptococcal infection, particularly murine and rabbit models, and demonstrate how these models in conjunction with the application of emerging technologies have advanced our knowledge about this disease. In the current era of increasingly more stringent regulations on the use of laboratory animals, it is no longer acceptable to most Institutional Animal Care and Use Committees for the investigator to allow the experimental animals to die of infection. Mice are the most frequently used species for cryptococcal models and can be infected by one of several routes. Intraperitoneal infection using 105 to 107 yeast cells is technically easy to master, and many mice can be infected quickly. Human cryptococcosis is acquired via inhalation, and thus, pulmonary models of infection are better mimics of the natural disease progression. The use of rabbits in models of fungal infection has been much more limited than the use of rodents. Prevention of infection is even more desirable, and vaccine studies in animal models have been done in the field of cryptococcosis.
Citation:
Clemons K, Stevens D.
2011.
Cryptococcosis in Experimental Animals: Lessons Learned,
p 473-488.
In
Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed),
Cryptococcus.
ASM Press, Washington, DC.
doi: 10.1128/9781555816858.ch35
References
/content/book/10.1128/9781555816858.ch35
1.
Adler-Moore, J., and, R. T. Proffitt. 2002. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J. Antimicrob. Chemother. 49(Suppl 1): 21– 30.
2.
Aguirre, K.,, E. A. Havell,, G. W. Gibson, and, L. L. Johnson. 1995. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63: 1725– 1731.
3.
Aguirre, K. M.,, G. W. Gibson, and, L. L. Johnson. 1998. Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge. Infect. Immun. 66: 4018– 4024.
4.
Barchiesi,, F.,, M. Cogliati,, M. C. Esposto,, E. Spreghini, A. M. Schimizzi,, B. L. Wickes,, G. Scalise, and, M. A. Viviani. 2005. Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J. Infect. 51: 10– 16.
5.
Beenhouwer,, D. O.,, S. Shapiro,, M. Feldmesser,, A. Casadevall, and, M. D. Scharff. 2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69: 6445– 6455.
6.
Biondo,, C.,, A. Midiri,, L. Messina,, F. Tomasello,, G. Garufi, M. R. Catania,, M. Bombaci,, C. Beninati,, G. Teti, and, G. Mancuso. 2005. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur. J. Immunol. 35: 870– 878.
7.
Blackstock, R.,, K. L. Buchanan,, A. M. Adesina, and, J. W. Murphy. 1999. Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect. Immun. 67: 3601– 3609.
8.
Blackstock,, R.,, K. L. Buchanan,, R. Cherniak, T. G. Mitchell,, B. Wong,, A. Bartiss,, L. Jackson, and, J. W. Murphy. 1999. Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia 147: 1– 11.
9.
Blackstock, R., and, J. W. Murphy. 2004. Role of interleukin-4 in resistance to Cryptococcus neoformans infection. Am. J. Respir. Cell. Mol. Biol. 30: 109– 117.
10.
Blasi,, E.,, R. Barluzzi,, R. Mazzolla,, L. Pitzurra,, M. Puliti,, S. Saleppico, and, F. Bistoni. 1995. Biomolecular events involved in anticryptococcal resistance in the brain. Infect. Immun. 63: 1218– 1222.
11.
Brummer, E., and, K. V. Clemons. 1987. Animal models in systemic mycoses, p. 79–95. In M. Miyaji (ed.), Animal Models in Medical Mycology. CRC Press, Boca Raton, FL.
12.
Brummer, E., and, D. A. Stevens. 2010. Collectins and fungal pathogens: roles of surfactant proteins and mannose binding in host resistance. Med. Mycol. 48: 16– 28.
13.
Buchanan, K. L., and, H. A. Doyle. 2000. Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect. Immun. 68: 456– 462.
14.
Buchanan, K. L., and, J. W. Murphy. 1994. Regulation of cytokine production during the expression phase of the anticryptococcal delayedtype hypersensitivity response. Infect. Immun. 62: 2930– 2939.
15.
Byron,, J. K.,, K. V. Clemons,, J. H. McCusker,, R. W. Davis, and, D. A. Stevens. 1995. Pathogenicity of Saccharomyces cerevisiae in complement factor fivedeficient mice. Infect. Immun. 63: 478– 485.
16.
Capilla, J.,, K. V. Clemons, and, D. A. Stevens. 2007. Animal models: an important tool in mycology. Med. Mycol. 45: 657– 684.
17.
Capilla,, J.,, C. M. Maffei,, K. V. Clemons,, R. A. Sobel, and, D. A. Stevens. 2006. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med. Mycol. 44: 601– 610.
18.
Carroll, S. F.,, L. Guillot, and, S. T. Qureshi. 2007. Mammalian model hosts of cryptococcal infection. Comp. Med. 57: 9– 17.
19.
Casadevall, A., and, J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
20.
Casadevall, A.,, A. L. Rosas, and, J. D. Nosanchuk. 2000. Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3: 354– 358.
21.
Chaturvedi, S.,, P. Ren,, S. D. Narasipura, and, V. Chaturvedi. 2005. Selection of optimal host strain for molecular pathogenesis studies on Cryptococcus gattii. Mycopathologia 160: 207– 215.
22.
Chen,, S. C.,, M. Muller, J. Z. Zhou,, L. C. Wright, and, T. C. Sorrell. 1997. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J. Infect. Dis. 175: 414– 420.
23.
Chung, S.,, P. Mondon,, Y. C. Chang, and, K. J. Kwon-Chung. 2003. Cryptococcus neoformans with a mutation in the tetratricopeptide repeatcontaining gene, CCN1, causes subcutaneous lesions but fails to cause systemic infection. Infect. Immun. 71: 1988– 1994.
24.
Clancy,, C. J.,, M. H. Nguyen,, R. Alandoerffer,, S. Cheng,, K. Iczkowski,, M. Richardson, and, J. R. Graybill. 2006. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152: 2247– 2255.
25.
Clemons, K.,, J. Capilla, and, D. A. Stevens. 2007. Experimental animal models of coccidioidomycosis. Ann. NY Acad. Sci. 1111: 208– 224.
26.
Clemons, K. V.,, R. Azzi, and, D. A. Stevens. 1996. Experimental systemic cryptococcosis in SCID mice. J. Med. Vet. Mycol. 34: 331– 335.
27.
Clemons, K. V.,, E. Brummer, and, D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38: 460– 464.
28.
Clemons,, K. V.,, G. Grunig, R. A. Sobel,, L. F. Mirels,, D. M. Rennick, and, D. A. Stevens. 2000. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin. Exp. Immunol. 122: 186– 191.
29.
Clemons, K. V.,, J. E. Lutz, and, D. A. Stevens. 2001. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob. Agents Chemother. 45: 686– 689.
30.
Clemons,, K. V.,, J. H. McCusker,, R. W. Davis, and, D. A. Stevens. 1994. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J. Infect. Dis. 169: 859– 867.
31.
Clemons,, K. V.,, P. Kamberi, T. M. Chiller,, R. A. Sobel,, E. Brummer,, J. Kolls, and, D. A. Stevens. 2005. Effects of interferon-γ gene therapy in the murine central nervous system and concentrations in cerebrospinal fluid after intrathecal or intracerebral administration. Biotechnology 4: 11– 18.
32.
Clemons, K. V., and, D. A. Stevens. 2006. Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: what can we learn from them? Med. Mycol. 44(Suppl. 1):S119–S126.
33.
Clemons, K. V., and, D. A. Stevens. 2006. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr. Opin. Infect. Dis. 19: 360– 364.
34.
Clemons, K. V., and, D. A. Stevens. 1998. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42: 899– 902.
35.
Clemons, K. V., and, D. A. Stevens. 2005. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med. Mycol. 43(Suppl 1): S101– S110.
36.
Clemons, K. V., and, D. A. Stevens. 2001. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin. Respir. Infect. 16: 60– 66.
37.
Clemons, K. V., and, D. A. Stevens. 2002. Immunomodulation of fungal infections: do immunomodulators have a role in treating mycoses? EOS Riv. Immunol. Immunofarmacol. 22: 29– 32.
38.
Cox,, G. M.,, T. S. Harrison,, H. C. McDade,, C. P. Taborda,, G. Heinrich,, A. Casadevall, and, J. R. Perfect. 2003. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect. Immun. 71: 173– 180.
39.
Cox,, G. M.,, H. C. McDade,, S. C. Chen,, S. C. Tucker,, M. Gottfredsson,, L. C. Wright,, T. C. Sorrell,, S. D. Leidich,, A. Casadevall,, M. A. Ghannoum, and, J. R. Perfect. 2001. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol. Microbiol. 39: 166– 175.
40.
Cox,, G. M.,, J. Mukherjee, G. T. Cole,, A. Casadevall, and, J. R. Perfect. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68: 443– 448.
41.
Crouch, E.,, K. Hartshorn, and, I. Ofek. 2000. Collectins and pulmonary innate immunity. Immunol. Rev. 173: 52– 65.
42.
Cutler, J. E. 1976. Acute systemic candidiasis in normal and congenitally thymicdeficient (nude) mice. J. Reticuloendothel. Soc. 19: 121– 124.
43.
Dan,, J. M.,, R. M. Kelly,, C. K. Lee, and, S. M. Levitz. 2008. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect. Immun. 76: 2362– 2367.
44.
Datta, K.,, A. Lees, and, L. A. Pirofski. 2008. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin. Vaccine Immunol. 15: 1176– 1187.
45.
Decken,, K.,, G. Kohler,, K. PalmerLehmann,, A. Wunderlin,, F. Mattner,, J. Magram,, M. K. Gately, and, G. Alber. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66: 4994– 5000.
46.
Deepe,, G. S.,, Jr., L. Romani, V. L. Calich,, G. Huffnagle,, C. Arruda,, E. E. MolinariMadlum, and, J. R. Perfect. 2000. Knockout mice as experimental models of virulence. Med. Mycol. 38(Suppl 1): 87– 98.
47.
Devi, S. J. 1996. Preclinical efficacy of a glucuronoxylomannantetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14: 841– 844.
48.
Diamond,, D. M.,, M. Bauer, B. E. Daniel,, M. A. Leal,, D. Johnson,, B. K. Williams,, A. M. Thomas,, J. C. Ding,, L. Najvar,, J. R. Graybill, and, R. A. Larsen. 1998. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob. Agents Chemother. 42: 528– 533.
49.
Ding,, J. C.,, M. Bauer, D. M. Diamond,, M. A. Leal,, D. Johnson,, B. K. Williams,, A. M. Thomas,, L. Najvar,, J. R. Graybill, and, R. A. Larsen. 1997. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41: 1589– 1593.
50.
Dobrick, P.,, K. Miksits, and, H. Hahn. 1995. L3T4(CD4)-, Lyt-2(CD8)- and Mac-1(CD11b)phenotypic leukocytes in murine cryptococcal meningoencephalitis. Mycopathologia 131: 159– 166.
51.
Dromer, F., and, J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti- Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163: 1114– 1120.
52.
Dromer, F.,, J. Charreire,, A. Contrepois,, C. Carbon, and, P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti- Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55: 749– 752.
53.
Dromer, F.,, C. Perronne,, J. Barge, J. L. Vilde, and, P. Yeni. 1989. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin. Exp. Immunol. 78: 412– 417.
54.
D’Souza,, C. A.,, F. Hagen,, T. Boekhout,, G. M. Cox, and, J. Heitman. 2004. Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals. Curr. Genet. 46: 92– 102.
55.
Erickson,, T.,, L. Liu,, A. Gueyikian,, X. Zhu,, J. Gibbons, and, P. R. Williamson. 2001. Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol. Microbiol. 42: 1121– 1131.
56.
Feldmesser, M.,, A. Mednick, and, A. Casadevall. 2002. Antibodymediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70: 1571– 1580.
57.
Fleuridor, R.,, A. Lees, and, L. Pirofski. 2001. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166: 1087– 1096.
58.
Fraser,, J. A.,, S. S. Giles,, E. C. Wenink,, S. G. GeunesBoyer,, J. R. Wright,, S. Diezmann,, A. Allen,, J. E. Stajich,, F. S. Dietrich,, J. R. Perfect, and, J. Heitman. 2005. Samesex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437: 1360– 1364.
59.
Fries, B. C., and, A. Casadevall. 1998. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178: 1761– 1766.
60.
Fromtling, R. A.,, R. Blackstock,, N. K. Hall, and, G. S. Bulmer. 1979. Immunization of mice with an avirulent pseudohyphal form of Cryptococcus neoformans. Mycopathologia 68: 179– 181.
61.
Fromtling, R. A.,, A. M. Kaplan, and, H. J. Shadomy. 1983. Immunization of mice with stable, acapsular, yeastlike mutants of Cryptococcus neoformans. Sabouraudia 21: 113– 119.
62.
Fuchs, B. B., and, E. Mylonakis. 2006. Using nonmammalian hosts to study fungal virulence and host defense. Curr. Opin. Microbiol. 9: 346– 351.
63.
Giles,, S. S.,, A. K. Zaas,, M. F. Reidy,, J. R. Perfect, and, J. R. Wright. 2007. Cryptococcus neoformans is resistant to surfactant protein A mediated host defense mechanisms. PLoS ONE 2: e1370.
64.
Granger, D. L.,, J. R. Perfect, and, D. T. Durack. 1985. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Invest. 76: 508– 516.
65.
Graybill, J. R.,, R. Bocanegra,, C. Lambros, and, M. F. Luther. 1997. Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. J. Med. Vet. Mycol. 35: 243– 247.
66.
Graybill,, J. R.,, P. C. Craven,, L. F. Mitchell, and, D. J. Drutz. 1978. Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis. Antimicrob. Agents Chemother. 14: 659– 667.
67.
Graybill, J. R., and, D. J. Drutz. 1978. Host defense in cryptococcosis. II. Cryptococcosis in the nude mouse. Cell. Immunol. 40: 263– 274.
68.
Graybill, J. R., and, L. Mitchell. 1980. Treatment of murine cryptococcosis with minocycline and amphotericin B. Sabouraudia 18: 137– 144.
69.
Graybill, J. R.,, L. Mitchell, and, D. J. Drutz. 1979. Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J. Infect. Dis. 140: 546– 552.
70.
Guerrero, A., and, B. C. Fries. 2008. Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response. Infect. Immun. 76: 4322– 4331.
71.
Hamilton, A. J., and, J. Goodley. 1996. Virulence factors of Cryptococcus neoformans. Curr. Top. Med. Mycol. 7: 19– 42.
72.
Hamilton, J. D., and, D. M. Elliott. 1975. Combined activity of amphotericin B and 5fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J. Infect. Dis. 131: 129– 137.
73.
Hay, R. J., and, E. Reiss. 1978. Delayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformans. Infect. Immun. 22: 72– 79.
74.
Hernandez,, Y.,, S. Arora,, J. R. Erb-Downward,, R. A. McDonald,, G. B. Toews, and, G. B. Huffnagle. 2005. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J. Immunol. 174: 1027– 1036.
75.
Hill, J. O. 1992. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175: 1685– 1695.
76.
Hill, J. O., and, K. M. Aguirre. 1994. CD4+ T celldependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J. Immunol. 152: 2344– 2350.
77.
Hoag,, K. A.,, M. F. Lipscomb,, A. A. Izzo, and, N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell. Mol. Biol. 17: 733– 739.
78.
Hoag,, K. A.,, N. E. Street,, G. B. Huffnagle, and, M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell. Mol. Biol. 13: 487– 495.
79.
Hobbs,, M. M.,, J. R. Perfect,, D. L. Granger, and, D. T. Durack. 1990. Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun. 58: 2115– 2119.
80.
Hogan, L. H.,, B. S. Klein, and, S. M. Levitz. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9: 469– 488.
81.
Hostetler,, J. S.,, K. V. Clemons,, L. H. Hanson, and, D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36: 2656– 2660.
82.
Huffnagle,, G. B.,, M. B. Boyd,, N. E. Street, and, M. F. Lipscomb. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160: 2393– 2400.
83.
Huffnagle, G. B., and, G. S. Deepe. 2003. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr. Opin. Microbiol. 6: 344– 350.
84.
Huffnagle, G. B., and, M. F. Lipscomb. 1992. Animal model of human disease: pulmonary cryptococcosis. Am. J. Pathol. 141: 1517– 1520.
85.
Huffnagle, G. B., and, M. F. Lipscomb. 1998. Cells and cytokines in pulmonary cryptococcosis. Res. Immunol. 149: 387– 396.; discussion 512– 514.
86.
Huffnagle,, G. B.,, M. F. Lipscomb,, J. A. Lovchik,, K. A. Hoag, and, N. E. Street. 1994. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55: 35– 42.
87.
Huffnagle, G. B., and, L. K. McNeil. 1999. Dissemination of C. neoformans to the central nervous system: role of chemokines, Th1 immunity and leukocyte recruitment. J. Neurovirol. 5: 76– 81.
88.
Huffnagle, G. B.,, J. L. Yates, and, M. F. Lipscomb. 1991. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173: 793– 800.
89.
Huffnagle, G. B.,, J. L. Yates, and, M. F. Lipscomb. 1991. T cellmediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59: 1423– 1433.
90.
Irokanulo, E. A., and, C. O. Akueshi. 1995. Virulence of Cryptococcus neoformans serotypes A, B, C and D for four mouse strains. J. Med. Microbiol. 43: 289– 293.
91.
Jain, N., and, B. C. Fries. 2008. Phenotypic switching of Cryptococcus neoformans and Cryptococcus gattii. Mycopathologia 166: 181– 188.
92.
Kamberi,, P.,, R. A. Sobel,, K. V. Clemons,, D. A. Stevens,, D. Pappagianis, and, P. L. Williams. 2003. A murine model of coccidioidal meningitis. J. Infect. Dis. 187: 453– 460.
93.
Kawakami,, K.,, Y. Koguchi,, M. H. Qureshi,, Y. Kinjo,, S. Yara,, A. Miyazato,, M. Kurimoto,, K. Takeda,, S. Akira, and, A. Saito. 2000. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol. Lett. 186: 121– 126.
94.
Kawakami,, K.,, Y. Koguchi,, M. H. Qureshi,, A. Miyazato,, S. Yara,, Y. Kinjo,, Y. Iwakura,, K. Takeda,, S. Akira,, M. Kurimoto, and, A. Saito. 2000. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFNgamma production by NK cells. J. Immunol. 165: 941– 947.
95.
Kawakami, K.,, M. H. Qureshi,, Y. Koguchi,, K. Naka-jima, and, A. Saito. 1999. Differential effect of Cryptococcus neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with lipopolysaccharide and gamma interferon. FEMS Microbiol. Lett. 175: 87– 94.
96.
Kawakami,, K.,, K. Shibuya,, M. H. Qureshi,, T. Zhang,, Y. Koguchi,, M. Tohyama,, Q. Xie,, S. Naoe, and, A. Saito. 1999. Chemokine responses and accumulation of inflammatory cells in the lungs of mice infected with highly virulent Cryptococcus neoformans: effects of interleukin-12. FEMS Immunol. Med. Microbiol. 25: 391– 402.
97.
Kawakami, K.,, M. Tohyama,, X. Qifeng, and, A. Saito. 1997. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12. Infect. Immun. 65: 1307– 1312.
98.
Kawakami, K.,, M. Tohyama,, Q. Xie, and, A. Saito. 1996. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol. 104: 208– 214.
99.
Kleinschek,, M. A.,, U. Muller, S. J. Brodie,, W. Stenzel,, G. Kohler,, W. M. Blumenschein,, R. K. Straubinger,, T. McClanahan,, R. A. Kastelein, and, G. Alber. 2006. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J. Immunol. 176: 1098– 1106.
100.
Kullberg, B. J. 1997. Trends in immunotherapy of fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 16: 51– 55.
101.
Kwon-Chung, K. J.,, I. Polacheck, and, T. J. Popkin. 1982. Melaninlacking mutants of Cryptococcus neoformans and their virulence for mice. J. Bacteriol. 150: 1414– 1421.
102.
Kwon-Chung,, K. J.,, B. L. Wickes,, L. Stockman, G. D. Roberts,, D. Ellis, and, D. H. Howard. 1992. Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii. Infect. Immun. 60: 1869– 1874.
103.
Larsen, R. A.,, M. Bauer,, A. M. Thomas, and, J. R. Graybill. 2004. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob. Agents Chemother. 48: 985– 991.
104.
Larsen,, R. A.,, M. Bauer, A. M. Thomas,, A. Sanchez,, D. Citron,, M. Rathbun, and, T. S. Harrison. 2005. Correspondence of in vitro and in vivo fluconazole doseresponse curves for Cryptococcus neoformans. Antimicrob. Agents Chemother. 49: 3297– 3301.
105.
Larsen,, R. A.,, M. Bauer, J. M. Weiner,, D. M. Diamond,, M. E. Leal,, J. C. Ding,, M. G. Rinaldi, and, J. R. Graybill. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. An-timicrob. Agents Chemother. 40: 2178– 2182.
106.
Larsen,, R. A.,, P. G. Pappas,, J. Perfect, J. A. Aberg,, A. Casadevall,, G. A. Cloud,, R. James,, S. Filler, and, W. E. Dismukes. 2005. Phase I evaluation of the safety and pharmacokinetics of murinederived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49: 952– 958.
107.
Lin, X.,, K. Nielsen,, S. Patel, and, J. Heitman. 2008. Impact of mating type, serotype, and ploidy on the virulence of Cryptococcus neoformans. Infect. Immun. 76: 2923– 2938.
108.
Liu,, O. W.,, M. J. Kelly,, E. D. Chow, and, H. D. Madhani. 2007. Parallel betahelix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans. Eukaryot. Cell 6: 630– 640.
109.
Loftus,, B. J.,, E. Fung,, P. Roncaglia,, D. Rowley,, P. Amedeo,, D. Bruno,, J. Vamathevan,, M. Miranda,, I. J. Anderson,, J. A. Fraser,, J. E. Allen,, I. E. Bosdet,, M. R. Brent,, R. Chiu,, T. L. Doering,, M. J. Donlin,, C. A. D’Souza,, D. S. Fox,, V. Grinberg,, J. Fu,, M. Fukushima,, B. J. Haas,, J. C. Huang,, G. Janbon,, S. J. Jones,, H. L. Koo,, M. I. Krzywinski,, J. K. KwonChung,, K. B. Lengeler,, R. Maiti,, M. A. Marra,, R. E. Marra,, C. A. Mathewson,, T. G. Mitchell,, M. Pertea,, F. R. Riggs,, S. L. Salzberg,, J. E. Schein,, A. Shvartsbeyn,, H. Shin,, M. Shumway,, C. A. Specht,, B. B. Suh,, A. Tenney,, T. R. Utterback,, B. L. Wickes,, J. R. Wortman,, N. H. Wye,, J. W. Kronstad,, J. K. Lodge,, J. Heitman,, R. W. Davis,, C. M. Fraser, and, R. W. Hyman. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307: 1321– 1324.
110.
Lortholary, O.,, L. Improvisi,, C. Fitting, J. M. Cavaillon, and, F. Dromer. 2002. Influence of gender and age on course of infection and cytokine responses in mice with disseminated Cryptococcus neoformans infection. Clin. Microbiol. Infect. 8: 31– 37.
111.
Lortholary,, O.,, L. Improvisi,, N. Rayhane,, F. Gray,, C. Fitting, J. M. Cavaillon, and, F. Dromer. 1999. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect. Immun. 67: 6314– 6320.
112.
Lovchik, J.,, M. Lipscomb, and, C. R. Lyons. 1997. Expression of lung inducible nitric oxide synthase protein does not correlate with nitric oxide production in vivo in a pulmonary immune response against Cryptococcus neoformans. J. Immunol. 158: 1772– 1778.
113.
Lovchik, J. A.,, C. R. Lyons, and, M. F. Lipscomb. 1995. A role for gamma interferoninduced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell. Mol. Biol. 13: 116– 124.
114.
Luberto,, C.,, B. MartinezMarino,, D. Taraskiewicz,, B. Bolanos,, P. Chitano, D. L. Toffaletti,, G. M. Cox,, J. R. Perfect,, Y. A. Hannun,, E. Balish, and, M. Del Poeta. 2003. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J. Clin. Invest. 112: 1080– 1094.
115.
Lutz, J. E.,, K. V. Clemons, and, D. A. Stevens. 2000. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J. Antimicrob. Chemother. 46: 437– 442.
116.
Macher,, A. M.,, J. E. Bennett,, J. E. Gadek, and, M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120: 1686– 1690.
117.
Maffei,, C. M.,, L. F. Mirels,, R. A. Sobel,, K. V. Clemons, and, D. A. Stevens. 2004. Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect. Immun. 72: 2338– 2349.
118.
Magee, D. M., and, R. A. Cox. 1996. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect. Immun. 64: 3609– 3613.
119.
Mansour,, M. K.,, L. E. Yauch,, J. B. Rottman, and, S. M. Levitz. 2004. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72: 1746– 1754.
120.
Marquis, G.,, S. Montplaisir,, M. Pelletier,, S. Mousseau, and, P. Auger. 1985. Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun. 47: 282– 287.
121.
Marquis, G.,, S. Montplaisir,, M. Pelletier,, S. Mousseau, and, P. Auger. 1985. Genetic resistance to murine cryptococcosis: the beige mutation (ChediakHigashi syndrome) in mice. Infect. Immun. 47: 288– 293.
122.
McClelland, E. E.,, P. Bernhardt, and, A. Casadevall. 2006. Estimating the relative contributions of virulence factors for pathogenic microbes. Infect. Immun. 74: 1500– 1504.
123.
McClelland, E. E.,, D. L. Granger, and, W. K. Potts. 2003. Major histocompatibility complexdependent susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 71: 4815– 4817.
124.
McClelland,, E. E.,, W. T. Perrine,, W. K. Potts, and, A. Casadevall. 2005. Relationship of virulence factor expression to evolved virulence in mousepassaged Cryptococcus neoformans lines. Infect. Immun. 73: 7047– 7050.
125.
Missall, T. A.,, M. E. Pusateri, and, J. K. Lodge. 2004. Thiol peroxidase is critical for virulence and resistance to nitric oxide and peroxide in the fungal pathogen, Cryptococcus neoformans. Mol. Microbiol. 51: 1447– 1458.
126.
Mitchell, T. G., and, J. R. Perfect. 1995. Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8: 515– 548.
127.
Mody,, C. H.,, M. F. Lipscomb,, N. E. Street, and, G. B. Toews. 1990. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. ]. Immunol. 144: 1472– 1477.
128.
Monga, D. P.,, R. Kumar,, L. N. Mohapatra, and, A. N. Malaviya. 1979. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect. Immun. 26: 1– 3.
129.
Monga, D. P.,, R. Kumar,, L. N. Mohapatra, and, A. N. Malaviya. 1980. Experimental cryptococcosis in normal and T cell deficient mice. Indian]. Med. Res. 72: 641– 649.
130.
Mukherjee, J.,, A. Casadevall, and, M. D. Scharff. 1993. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannantetanus toxoid conjugate immunization. J. Exp. Med. 177: 1105– 1116.
131.
Mukherjee, J.,, M. Feldmesser,, M. D. Scharff, and, A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39: 1398– 1405.
132.
Mukherjee, J.,, M. D. Scharff, and, A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60: 4534– 4541.
133.
Muller,, U.,, W. Stenzel,, G. Kohler,, C. Werner,, T. Polte,, G. Hansen,, N. Schutze,, R. K. Straubinger,, M. Blessing,, A. N. McKenzie,, F. Brombacher, and, G. Alber. 2007. IL-13 induces diseasepromoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179: 5367– 5377.
134.
Mylonakis, E., and, A. Aballay. 2005. Worms and flies as genetically tractable animal models to study hostpathogen interactions. Infect. Immun. 73: 3833– 3841.
135.
Mylonakis,, E.,, F. M. Ausubel,, J. R. Perfect,, J. Heitman, and, S. B. Calderwood. 2002. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc. Nati. Acad. Sci. USA 99: 15675– 15680.
136.
Mylonakis,, E.,, A. Idnurm,, R. Moreno, J. El Khoury,, J. B. Rottman,, F. M. Ausubel,, J. Heitman, and, S. B. Calderwood. 2004. Cryptococcus neoformans Kin1 protein kinase homologue, identified through a Caenorhabditis elegans screen, promotes virulence in mammals. Mol. Microbiol. 54: 407– 419.
137.
Mylonakis,, E.,, R. Moreno,, J. B. El Khoury,, A. Idnurm,, J. Heitman,, S. B. Calderwood,, F. M. Ausubel, and, A. Diener. 2005. Gallería mellonelL• as a model system to study Cryptococcus neoformans pathogenesis. Infect. Immun. 73: 3842– 3850.
138.
Najvar, L. K.,, R. Bocanegra, and, J. R. Graybill. 1999. An alternative animal model for comparison of treatments for cryptococcal meningitis. Antimicrob. Agents Chemother. 43: 413– 414.
139.
Nakamura,, K.,, T. Kinjo,, S. Saijo,, A. Miyazato,, Y. Adachi,, N. Ohno,, J. Fujita,, M. Kaku,, Y. Iwakura, and, K. Kawakami. 2007. Dectin-1 is not required for the host defense to Cryptococcus neoformans. Microbiol. Immunol. 51: 1115– 1119.
140.
Nielsen,, K.,, G. M. Cox,, A. P. Litvintseva,, E. Mylonakis, S. D. Malliaris,, D. K. Benjamin, Jr.,, S. S. Giles,, T. G. Mitchell,, A. Casadevall,, J. R. Perfect, and, J. Heitman. 2005. Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect. Immun. 73: 4922– 4933.
141.
Nielsen,, K.,, G. M. Cox,, P. Wang, D. L. Toffaletti,, J. R. Perfect, and, J. Heitman. 2003. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and α isolates. Infect. Immun. 71: 4831– 4841.
142.
Nishimura, K., and, M. Miyaji. 1979. Histopathological studies on experimental cryptococcosis in nude mice. Mycopathologia 68: 145– 153.
143.
Odom,, A.,, S. Muir,, E. Lim, D. L. Toffaletti,, J. Perfect, and, J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16: 2576– 2589.
144.
Pal, M. 2005. Pathogenicity of environmental strains of Cryptococcus neoformans var neoformans in murine model. Rev. Iberoam. Micol. 22: 129.
145.
Pappas,, P. G.,, B. Bustamante,, E. Ticona,, R. J. Hamill,, P. C. Johnson,, A. Reboli,, J. Aberg,, R. Hasbun, and, H. H. Hsu. 2004. Recombinant interferon-γ 1b as adjunctive therapy for AIDSrelated acute cryptococcal meningitis. J. Infect. Dis. 189: 2185– 2191.
146.
Perfect, J. R. 2005. Cryptococcus neoformans: a sugarcoated killer with designer genes. FEMS Immunol. Med. Microbiol. 45: 395– 404.
147.
Perfect, J. R. 1990. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev. Infect. Dis. 12(Suppl 3): S299– S302.
148.
Perfect,, J. R.,, G. M. Cox,, R. K. Dodge, and, W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40: 1910– 1913.
149.
Perfect, J. R., and, D. T. Durack. 1985. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob. Agents Chemother. 28: 751– 755.
150.
Perfect, J. R., and, D. T. Durack. 1982. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J. Infect. Dis. 146: 429– 435.
151.
Perfect,, J. R.,, M. M. Hobbs,, D. L. Granger, and, D. T. Durack. 1988. Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity. Infect. Immun. 56: 849– 854.
152.
Perfect, J. R.,, S. D. Lang, and, D. T. Durack. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am. J. Pathol. 101: 177– 194.
153.
Perfect, J. R.,, S. D. Lang, and, D. T. Durack. 1981. Influence of agglutinating antibody in experimental cryptococcal meningitis. Br. J. Exp. Pathol. 62: 595– 599.
154.
Perfect,, J. R.,, B. Wong, Y. C. Chang,, K. J. Kwon-Chung, and, P. R. Williamson. 1998. Cryptococcus neoformans: virulence and host defences. Med. Mycol. 36(Suppl 1): 79– 86.
155.
Perfect, J. R., and, K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J. Antimicrob. Chemother. 33: 73– 81.
156.
Petzold,, E. W.,, U. Himmelreich,, E. Mylonakis,, T. Rude,, D. Toffaletti,, G. M. Cox,, J. L. Miller, and, J. R. Perfect. 2006. Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect. Immun. 74: 5877– 5887.
157.
Reese,, A. J.,, A. Yoneda, J. A. Breger,, A. Beauvais,, H. Liu,, C. L. Griffith,, I. Bose,, M. J. Kim,, C. Skau,, S. Yang,, J. A. Sefko,, M. Osumi,, J. P. Latge,, E. Mylonakis, and, T. L. Doering. 2007. Loss of cell wall α(1–3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol. Microbiol. 63: 1385– 1398.
158.
Reiss, F., and, E. AltureWerber. 1976. Immunization of mice with a mutant of Cryptococcus neoformans. Characterization of the mutant, actively acquired resistance to experimental cryptococcosis in mice. Dermatologica 152: 16– 22.
159.
Rhodes, J. C. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23: 225– 234.
160.
Rhodes, J. C.,, L. S. Wicker, and, W. J. Urba. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 29: 494– 499.
161.
Rivera, J.,, J. Mukherjee,, L. M. Weiss, and, A. Casade-vall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168: 3419– 3427.
162.
Rivera, J.,, O. Zaragoza, and, A. Casadevall. 2005. Antibodymediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect. Immun. 73: 1141– 1150.
163.
Romani, L. 2004. Immunity to fungal infections. Nat. Rev. Immunol. 4: 1– 23.
164.
Rosas, A. L.,, J. D. Nosanchuk, and, A. Casadevall. 2001. Passive immunization with melaninbinding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect. Immun. 69: 3410– 3412.
165.
Rude,, T. H.,, D. L. Toffaletti,, G. M. Cox, and, J. R. Perfect. 2002. Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect. Immun. 70: 5684– 5694.
166.
Salas,, S. D.,, J. E. Bennett,, K. J. KwonChung,, J. R. Perfect, and, P. R. Williamson. 1996. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J. Exp. Med. 184: 377– 386.
167.
Salkowski, C. A., and, E. Balish. 1991. Cryptococcosis in beige mice: the effect of congenital defects in innate immunity on susceptibility. Can. J. Microbiol. 37: 128– 135.
168.
Salkowski, C. A., and, E. Balish. 1991. A monoclonal antibody to gamma interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosis. Infect. Immun. 59: 486– 493.
169.
Salkowski, C. A., and, E. Balish. 1990. Pathogenesis of Cryptococcus neoformans in congenitally immunodeficient beige athymic mice. Infect. Immun. 58: 3300– 3306.
170.
San-Blas,, G.,, L. R. Travassos,, B. C. Fries,, D. L. Goldman,, A. Casadevall,, A. K. Carmona,, T. F. Barros,, R. Puccia,, M. K. Hostetter,, S. G. Shanks,, V. M. Copping,, Y. Knox, and, N. A. Gow. 2000. Fungal morphogenesis and virulence. Med. Mycol. 38(Suppl 1): 79– 86.
171.
Schell,, W. A.,, G. M. De Almeida,, R. K. Dodge,, K. Okonogi, and, J. R. Perfect. 1998. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42: 2630– 2632.
172.
Sorensen,, K. N.,, K. V. Clemons,, and D. A. Stevens. 1999. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis. Mycopathologia 146: 53– 65.
173.
Staib, F., and, S. K. Mishra. 1975. Contributions to the strainspecific virulence of Cryptococcus neoformans. Animal experiments with two C. neoformans-strains isolated from bird manure. Preliminary report. Zentralbl. Bakteriol. Orig A 230: 81– 85. (In German.)
174.
Steen,, B. R.,, S. Zuyderduyn, D. L. Toffaletti,, M. Marra, S. J. Jones,, J. R. Perfect, and, J. Kronstad. 2003. Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot. Cell 2: 1336– 1349.
175.
Steenbergen, J. N., and, A. Casadevall. 2003. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect. 5: 667– 675.
176.
Steenbergen,, J. N.,, J. D. Nosanchuk,, S. D. Malliaris, and, A. Casadevall. 2003. Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect. Immun. 71: 4862– 4872.
177.
Steenbergen, J. N.,, H. A. Shuman, and, A. Casadevall. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. USA 98: 15245– 15250.
178.
Stevens, D. A. 1996. Animal models in the evaluation of antifungal drugs. J. Mycol. Med. 6: 7– 10.
179.
Stevens, D. A. 1997. Animal models of blastomycosis. Semin. Respir. Infect. 12: 196– 197.
180.
Stevens, D. A. 1986. Animal models to evaluate antifungal activity: utility of models of chronic deep mycoses, p. 153–157. In H. V. B. K. Iwata (ed.), In Vitro and In Vivo Evaluation of Antifungal Agents. Elsevier Science.
181.
Stevens,, D. A.,, B. J. Kullberg,, E. Brummer,, A. Casadevall,, M. G. Netea, and, A. M. Sugar. 2000. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 38(Suppl 1): 305– 315.
182.
Stevens,, D. A.,, T. J. Walsh,, F. Bistoni,, E. Cenci,, K. V. Clemons,, G. Del Sero,, C. Fe d’Ostiani,, B. J. Kullberg,, A. Mencacci,, E. Roilides, and, L. Romani. 1998. Cytokines and mycoses. Med. Mycol. 36(Suppl 1): 174– 182.
183.
Takemoto, K.,, Y. Yamamoto, and, Y. Ueda. 2006. Influence of the progression of cryptococcal meningitis on brain penetration and efficacy of AmBisome in a murine model. Chemotherapy 52: 271– 278.
184.
Toffaletti,, D. L.,, K. Nielsen,, F. Dietrich,, J. Heitman, and, J. R. Perfect. 2004. Cryptococcus neoformans mitochondrial genomes from serotype A and D strains do not influence virulence. Curr. Genet. 46: 193– 204.
185.
Torda, A.,, R. K. Kumar, and, P. D. Jones. 2001. The pathology of human and murine pulmonary infection with Cryptococcus neoformans var. gattii. Pathology 33: 475– 478.
186.
Torres-Rodriguez,, J. M.,, Y. Morera,, T. Baro,, J. M. Corominas, and, E. Castaneda. 2003. Pathogenicity of Cryptococcus neoformans var. gattii in an immunocompetent mouse model. Med. Mycol. 41: 59– 63.
187.
Tournu, H.,, J. Serneels, and, P. Van Dijck. 2005. Fungal pathogens research: novel and improved molecular approaches for the discovery of antifungal drug targets. Curr. Drug Targets 6: 909– 922.
188.
Uicker,, W. C.,, H. A. Doyle,, J. P. McCracken,, M. Langlois, and, K. L. Buchanan. 2005. Cytokine and chemokine expression in the central nervous system associated with protective cellmediated immunity against Cryptococcus neoformans. Med. Mycol. 43: 27– 38.
189.
van den Berg,, M. C.,, J. Z. Woerlee,, H. Ma, and, R. C. May. 2006. Sexdependent resistance to the pathogenic fungus Cryptococcus neoformans. Genetics 173: 677– 683.
190.
Walenkamp,, A. M.,, A. F. Verheul,, J. Scharringa, and, I. M. Hoepelman. 1999. Pulmonary surfactant protein A binds to Cryptococcus neoformans without promoting phagocytosis. Eur. J. Clin. Invest. 29: 83– 92.
191.
Wang,, P.,, C. B. Nichols,, K. B. Lengeler,, M. E. Cardenas,, G. M. Cox,, J. R. Perfect, and, J. Heitman. 2002. Matingtypespecific and nonspecific PAK kinases play shared and divergent roles in Cryptococcus neoformans. Eukaryot. Cell 1: 257– 272.
192.
Williams,, P. L.,, S. L. Leib,, P. Kamberi,, D. Leppert,, R. A. Sobel,, Y. D. Bifrare,, K. V. Clemons, and, D. A. Stevens. 2002. Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J. Infect. Dis. 186: 1692– 1695.
193.
Williams,, P. L.,, R. A. Sobel,, K. N. Sorensen,, K. V. Clemons,, L. M. Shuer,, S. S. Royaltey,, Y. Yao,, D. Pappagianis,, J. E. Lutz,, C. Reed,, M. E. River,, B. C. Lee,, S. U. Bhatti, and, D. A. Stevens. 1998. A model of coccidioidal meningoencephalitis and cerebrospinal vasculitis in the rabbit. J. Infect. Dis. 178: 1217– 1221.
194.
Wills,, E. A.,, I. S. Roberts,, M. Del Poeta,, J. Rivera,, A. Casadevall,, G. M. Cox, and, J. R. Perfect. 2001. Identification and characterization of the Cryptococcus neoformans phosphomannose isomeraseencoding gene, MAN1, and its impact on pathogenicity. Mol. Microbiol. 40: 610– 620.
195.
Wormley, F. L., Jr.,, G. M. Cox, and, J. R. Perfect. 2005. Evaluation of host immune responses to pulmonary cryptococcosis using a temperaturesensitive C. neoformans calcineurin A mutant strain. Microb. Pathog. 38: 113– 123.
196.
Wormley,, F. L.,, Jr., J. R. Perfect,, C. Steele, and, G. M. Cox. 2007. Protection against cryptococcosis by using a murine gamma interferonproducing Cryptococcus neoformans strain. Infect. Immun. 75: 1453– 1462.
197.
Wright, K. A.,, J. R. Perfect, and, W. Ritter. 1990. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J. Antimicrob. Chemother. 26: 387– 397.
198.
Yauch,, L. E.,, M. K. Mansour,, S. Shoham, J. B. Rottman, and, S. M. Levitz. 2004. Involvement of CD14, tolllike receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect. Immun. 72: 5373– 5382.
199.
Zhou, Q.,, R. A. Gault,, T. R. Kozel, and, W. J. Murphy. 2007. Protection from direct cerebral cryptococcus infection by interferon-γ-dependent activation of microglial cells. J. Immunol. 178: 5753– 5761.
200.
Zucker,, K. E.,, P. Kamberi, R. A. Sobel,, G. Cloud, D. N. Meli,, K. V. Clemons,, D. A. Stevens,, P. L. Williams, and, S. L. Leib. 2006. Temporal expression of inflammatory mediators in brain basilar artery vasculitis and cerebrospinal fluid of rabbits with coccidioidal meningitis. Clin. Exp. Immunol. 143: 458– 466.